Drug Trials Snapshots provide consumers and healthcare professionals with concise information about who participated in the key clinical trials that supported the original FDA approval of...

Jan 3, 2023 · Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the FDA’s CDER. See Table 1 for new approvals in 2022. …

Nov 30, 2022 · All the information you need about the 2022 FDA New Drug Approvals, including key clinical trial and sales data for each drug product.

Drug Trials Snapshots provide consumers with information about who participated in clinical trials that supported the FDA approval of new drugs. The information provided in these Snapshots …

An accounting of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval …

A comprehensive list of the US FDA’s Center for Drug Evaluation & Research (CDER)'s new drug therapy approvals for 2022. CDER approved 37 new drugs in 2022, down from 50 in 2021, …

Jan 21, 2023 · Seventeen of 2022’s new drugs were small molecules, accounting for 46%. That’s also a decline from 2021 and 2020, when small molecules made up 62 and 66% of the new …

FDA Novel Drug Approvals – November 2022 FDA Novel Drug Approvals – January 2023

Jan 23, 2023 · The year 2022 was a good, but perhaps not great year for innovation. According to the FDA’s Center for Drug Evaluation and Research’s (CDER) New Drug Therapy Approvals …

Since January 2015, CDER has shared information on the diversity of participants in clinical trials through the transparency initiative called Drug Trials Snapshots.